At a glance
- Originator Nonindustrial source
- Class Neuroprotectants; Small molecules
- Mechanism of Action AMPA receptor antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral ischaemia
Most Recent Events
- 08 Dec 1998 New profile
- 08 Dec 1998 Preclinical development for Cerebral ischaemia in Japan (Unknown route)